All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-07-24T15:34:49.000Z

FDA grants orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma

Jul 24, 2020
Share:

Bookmark this article

On July 23, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to cobomarsen (MRG-106), for the treatment of T-cell lymphoma.

Cobomarsen is an inhibitor of microRNA-155 (miR-155). Overexpression of miR-155 is associated with poor prognosis in a variety of T-cell lymphomas and several other blood cancers. In 2017, the FDA and the European Medicines Agency (EMA) granted orphan drug designation to cobomarsen for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (CTCL).

Cobomarsen is currently under investigation in two clinical trials, a phase II trial (NCT03837457) for CTCL and a phase I trial (NCT02580552) for adult T-cell leukemia/lymphoma (ATLL).  It has demonstrated promising results in patients with CTCL and ATLL, and it could be potentially used as a broad-based therapy for the treatment of other cancers with elevated levels of miR-155.

  1. GlobeNewswire. Cobomarsen receives orphan drug designation from the U.S. FDA for the treatment of T-cell lymphoma. https://www.globenewswire.com/news-release/2020/07/23/2066961/0/en/Cobomarsen-Receives-Orphan-Drug-Designation-From-the-U-S-FDA-for-the-Treatment-of-T-cell-Lymphoma.html. Published Jul 23, 2020. Accessed Jul 24, 2020.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox